Exosomes in Ovarian Cancer: Towards Precision Oncology
Authors:
- Maria Grazia PerroneMaria Grazia Perrone
- Silvana FilieriSFSilvana Filieri
- Amalia AzzaritiAmalia Azzariti
- Domenico ArmeniseDADomenico Armenise
- Olga Maria BaldelliOBOlga Maria Baldelli
- Anselma LiturriALAnselma Liturri
- Anna Maria SardanelliASAnna Maria Sardanelli
- Savina FerorelliSFSavina Ferorelli
- Morena MiciacciaMorena Miciaccia
- Antonio ScilimatiASAntonio Scilimati
Open Access
- 5 March 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (3) , 371
Abstract
Background: Identification of targetable biomarkers to improve early disease detection and overall patient outcomes is becoming an urgent need in clinical oncology. Ovarian cancer (OC) has one of the highest mortality rates among gynecological cancers. It is asymptomatic and almost always diagnosed at an advanced stage (III or IV), leading to a 5-year survival rate of approximately 35%. Methods: Current therapeutic approaches for OC are very limited and mainly consist of cytoreductive surgery and cisplatin plus taxane-based chemotherapy. No gender and tumor specific biomarkers are known. Exosomes, lipid bilayer vesicles of endocytic origin secreted by most cell types, represent sources of information for their involvement in the onset and progression of many diseases. Hence, research on exosome contents as tools and targets in precise oncology therapy provides knowledge essential to improving diagnosis and prognosis of the disease. Results: This review attempts to give an overview of how exosomes are implicated in ovarian carcinoma pathogenesis to trigger further cancer exosome-based investigations aimed at developing ovarian cancer fine-tuning diagnostic methodologies. Conclusions: It is essential to investigate exosome-based cancer drugs to advance understanding, improve treatment plans, create personalized strategies, ensure safety, and speed up clinical translation to increase patients’ overall survival and quality of life. Papers published in PubMed and Web of Science databases in the last five years (2020–2024) were used as a bibliographic source.Keywords
Funding Information
- “Hub Scienze della Vita della Regione Puglia, Ministero della Salute (Rome, Italy), Traiettoria 4 azione 4.1” (POS 4) (2023-UNBACLE-0242926)
This publication has 70 references indexed in Scilit:
- Isolation, identification, and challenges of extracellular vesicles: emerging players in clinical applicationsApoptosis, 2024
- Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgeryMedicinal Research Reviews, 2024
- The potential role of miRNA in regulating macrophage polarizationHeliyon, 2023
- Exosome Processing and Characterization Approaches for Research and Technology DevelopmentAdvanced Science, 2022
- Exosomes Derived Neuronal Markers: Immunoaffinity Isolation and CharacterizationNeuroMolecular Medicine, 2021
- Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6Human Cell, 2021
- Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detectionEuropean Journal of Medicinal Chemistry, 2019
- Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotypeCancer Letters, 2018
- Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug deliveryJournal of Controlled Release, 2014
- PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigationEuropean Journal of Medicinal Chemistry, 2014